Anteris Technologies (AVR.AX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AVR.AX · Stock Price

AUD 8.70+1.72 (+24.64%)

Market Cap: $612.9M

Historical price data

Market Cap: $612.9MPatents: 11Founded: 2003HQ: Sydney, Australia

Sector Ranking#15 in Regenerative Medicine

Overview

Anteris Technologies is an ASX-listed innovator focused on revolutionizing the treatment of aortic stenosis through its biomimetic DurAVR™ TAVR system. The company has achieved significant clinical milestones, demonstrating best-in-class hemodynamic performance with zero prosthesis-patient mismatch in small annuli patients and sustained positive one-year data. Its strategy centers on executing the landmark PARADIGM pivotal trial—the first all-comers, head-to-head TAVI trial—to secure regulatory approvals in the US and EU, positioning DurAVR™ as a potential new standard of care in the high-growth structural heart market.

Structural Heart DiseaseAortic Stenosis

Technology Platform

A biomimetic engineering platform focused on creating single-piece, native-shaped heart valve prostheses from proprietary anti-calcification tissue to replicate the hemodynamics and durability of a healthy human aortic valve.

Funding History

3

Total raised:$45M

PIPE$25MUndisclosedDec 15, 2022

PIPE$20MUndisclosedJun 15, 2021

IPOUndisclosedUndisclosedJun 15, 2004

Opportunities

Anteris targets the high-growth, multi-billion dollar TAVR market, with a specific focus on the underserved small annuli patient population (~30-40% of cases) where its valve demonstrates best-in-class hemodynamics and eliminates prosthesis-patient mismatch.

Successful execution of its pivotal PARADIGM trial could position DurAVR™ as a preferred option for younger, lower-risk patients due to its compelling durability proposition.

Risk Factors

The company faces significant clinical risk, as its future depends entirely on the success of the ongoing PARADIGM pivotal trial.

As a pre-revenue entity, it carries substantial funding and dilution risk to finance this trial and future commercialization.

Furthermore, it must overcome formidable commercial barriers to entry in a market dominated by well-capitalized giants like Edwards Lifesciences and Medtronic.

Competitive Landscape

Anteris competes in the TAVR market against established leaders Edwards Lifesciences and Medtronic, as well as Boston Scientific. Its strategy is based on disruptive performance differentiation—superior hemodynamics, elimination of patient-prosthesis mismatch, and a potential durability advantage—rather than direct commercial competition, aiming to carve out a significant niche in small annuli and durability-conscious patient segments.